301130 西点药业
已收盘 07-17 15:00:00
资讯
新帖
简况
西点药业最新公告:参加联盟组织药品集中带量采购续签药品中选
证券之星 · 07-12
西点药业最新公告:参加联盟组织药品集中带量采购续签药品中选
西点药业(301130.SZ)参加省级联盟组织药品集中带量采购续签药品中选
智通财经 · 07-12
西点药业(301130.SZ)参加省级联盟组织药品集中带量采购续签药品中选
西点药业(301130.SZ)累计回购403.65万股 耗资9341.89万元
智通财经 · 07-01
西点药业(301130.SZ)累计回购403.65万股 耗资9341.89万元
西点药业(301130)6月26日主力资金净卖出116.86万元
证券之星 · 06-27
西点药业(301130)6月26日主力资金净卖出116.86万元
西点药业(301130.SZ)拟10股派2.6元 于6月12日除权除息
智通财经 · 06-03
西点药业(301130.SZ)拟10股派2.6元 于6月12日除权除息
西点药业(301130.SZ)累计回购382.17万股 耗资8850.31万元
智通财经 · 06-03
西点药业(301130.SZ)累计回购382.17万股 耗资8850.31万元
西点药业:将参加吉林辖区上市公司网上集体业绩说明会
中国财富通 · 05-20
西点药业:将参加吉林辖区上市公司网上集体业绩说明会
西点药业:公司目前生产及在研产品中暂未使用生物合成相关技术
证券之星 · 05-13
西点药业:公司目前生产及在研产品中暂未使用生物合成相关技术
4月30日西点药业发布公告,其股东减持83.22万股
证券之星 · 04-30
4月30日西点药业发布公告,其股东减持83.22万股
西点药业(301130.SZ)主要股东国投高科及其一致行动人完成减持1.03%股份
智通财经 · 04-30
西点药业(301130.SZ)主要股东国投高科及其一致行动人完成减持1.03%股份
西点药业:公司发布的股东减持计划减持期间尚未到期,敬请关注公司后续发布的进展公告
证券之星 · 04-24
西点药业:公司发布的股东减持计划减持期间尚未到期,敬请关注公司后续发布的进展公告
西点药业(301130)2024年一季报简析:营收净利润同比双双增长
证券之星 · 04-24
西点药业(301130)2024年一季报简析:营收净利润同比双双增长
图解西点药业一季报:第一季度单季净利润同比增46.66%
证券之星 · 04-23
图解西点药业一季报:第一季度单季净利润同比增46.66%
图解西点药业年报:第四季度单季净利润同比增7.03%
证券之星 · 04-23
图解西点药业年报:第四季度单季净利润同比增7.03%
西点药业最新公告:一季度净利润1404.28万元 同比增长46.66%
证券之星 · 04-22
西点药业最新公告:一季度净利润1404.28万元 同比增长46.66%
西点药业(301130.SZ)发一季度业绩,净利润1404.28万元,同比增长46.66%
智通财经 · 04-22
西点药业(301130.SZ)发一季度业绩,净利润1404.28万元,同比增长46.66%
西点药业(301130.SZ)发2023年度业绩,净利润5050.24万元,同比增长24.01%
智通财经 · 04-22
西点药业(301130.SZ)发2023年度业绩,净利润5050.24万元,同比增长24.01%
西点药业(301130.SZ):盐酸艾司洛尔注射液获得注册申请受理
智通财经网 · 03-15
西点药业(301130.SZ):盐酸艾司洛尔注射液获得注册申请受理
西点药业(301130.SZ)已累计回购2.1081%股份 耗资约3809.6万元
智通财经网 · 03-14
西点药业(301130.SZ)已累计回购2.1081%股份 耗资约3809.6万元
西点药业(301130.SZ):枸橼酸钙境内生产药品注册上市许可申请获受理
智通财经网 · 02-02
西点药业(301130.SZ):枸橼酸钙境内生产药品注册上市许可申请获受理
暂无数据
公司概况
公司名称:
吉林省西点药业科技发展股份有限公司
所属行业:
医药制造业
上市日期:
2022-02-23
主营业务:
吉林省西点药业科技发展股份有限公司主营业务是化学药品原料药及制剂的研发、生产、销售。公司主要产品为复方硫酸亚铁叶酸片、利培酮口崩片、草酸艾司西酞普兰片、瑞香素胶囊、阿魏酸钠、阿魏酸钠、阿魏酸钠、阿魏酸钠。公司荣获“国家火炬计划重点高新技术企业”、等称号。
发行价格:
22.55
{"stockData":{"symbol":"301130","market":"SZ","secType":"STK","nameCN":"西点药业","latestPrice":23.05,"timestamp":1721199783000,"preClose":23.1,"halted":0,"volume":145280,"delay":0,"floatShares":58028100,"shares":80803900,"eps":0.6803,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.05,"latestTime":"07-17 15:00:00","open":23.02,"high":23.45,"low":22.83,"amount":3357700,"amplitude":0.0268,"askPrice":23.11,"askSize":17,"bidPrice":23.05,"bidSize":46,"shortable":0,"etf":0,"ttmEps":0.6803,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721266200000},"adr":0,"adjPreClose":23.1,"symbolType":"stock","openAndCloseTimeList":[[1721179800000,1721187000000],[1721192400000,1721199600000]],"highLimit":25.41,"lowLimit":20.79,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":80803943,"pbRate":2,"roa":"--","roe":"1.42%","epsLYR":0.625,"committee":0.004878,"marketValue":1863000000,"floatMarketCap":1338000000,"peRate":33.882111,"changeRate":-0.0022,"turnoverRate":0.0025,"status":1},"requestUrl":"/m/hq/s/301130/tweets","defaultTab":"tweets","newsList":[{"id":"2450330361","title":"西点药业最新公告:参加联盟组织药品集中带量采购续签药品中选","url":"https://stock-news.laohu8.com/highlight/detail?id=2450330361","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450330361?lang=zh_cn&edition=full","pubTime":"2024-07-12 16:28","pubTimestamp":1720772918,"startTime":"0","endTime":"0","summary":"西点药业公告,公司于近日参加省级联盟组织的药品集中带量采购的续签工作。截至公告披露日,公司生产的草酸艾司西酞普兰片已陆续中选《广东联盟阿莫西林等药品集中带量采购》《2024年河北省国家集采第一、二、四批药品到期续签采购项目》。草酸艾司西酞普兰片,是用于治疗抑郁症,治疗伴有或不伴有广场恐惧症的惊恐障碍的药品。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071200031557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301130","BK0239"],"gpt_icon":0},{"id":"2450720363","title":"西点药业(301130.SZ)参加省级联盟组织药品集中带量采购续签药品中选","url":"https://stock-news.laohu8.com/highlight/detail?id=2450720363","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450720363?lang=zh_cn&edition=full","pubTime":"2024-07-12 15:44","pubTimestamp":1720770276,"startTime":"0","endTime":"0","summary":"智通财经APP讯,西点药业 发布公告,公司于近日参加省级联盟组织的药品集中带量采购的续签工作。截至公告披露日,公司生产的草酸艾司西酞普兰片已陆续中选《广东联盟阿莫西林等药品集中带量采购》《2024年河北省国家集采第一、二、四批药品到期续签采购项目》。草酸艾司西酞普兰片,是用于治疗抑郁症,治疗伴有或不伴有广场恐惧症的惊恐障碍的药品,属于化学药品第6类。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149929.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301130","BK0239"],"gpt_icon":0},{"id":"2448963670","title":"西点药业(301130.SZ)累计回购403.65万股 耗资9341.89万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448963670","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448963670?lang=zh_cn&edition=full","pubTime":"2024-07-01 16:17","pubTimestamp":1719821876,"startTime":"0","endTime":"0","summary":"智通财经APP讯,西点药业(301130.SZ)公告,公司截至2024年6月28日以集中竞价交易方式回购公司股份403.65万股,占公司目前总股本的4.9953%,成交总金额为9341.89万元(不含交易费用)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1143533.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","301130"],"gpt_icon":0},{"id":"2446329004","title":"西点药业(301130)6月26日主力资金净卖出116.86万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446329004","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446329004?lang=zh_cn&edition=full","pubTime":"2024-06-27 09:12","pubTimestamp":1719450757,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月26日收盘,西点药业报收于24.61元,上涨8.27%,换手率1.46%,成交量8484.0手,成交额2034.53万元。近5日资金流向一览见下表:西点药业融资融券信息显示,融资方面,当日融资买入83.97万元,融资偿还72.29万元,融资净买入11.68万元。西点药业主营业务:化学药品原料药及制剂研发、生产、销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062700013421.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301130","BK0239"],"gpt_icon":0},{"id":"2440466412","title":"西点药业(301130.SZ)拟10股派2.6元 于6月12日除权除息","url":"https://stock-news.laohu8.com/highlight/detail?id=2440466412","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440466412?lang=zh_cn&edition=full","pubTime":"2024-06-03 19:02","pubTimestamp":1717412526,"startTime":"0","endTime":"0","summary":"智通财经APP讯,西点药业(301130.SZ)公告,公司2023年年度权益分派拟:向全体股东每10股派发现金股利2.6元(含税)。除权除息日为:2024年6月12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1130247.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301130","BK0239"],"gpt_icon":0},{"id":"2440507894","title":"西点药业(301130.SZ)累计回购382.17万股 耗资8850.31万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2440507894","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440507894?lang=zh_cn&edition=full","pubTime":"2024-06-03 17:57","pubTimestamp":1717408622,"startTime":"0","endTime":"0","summary":"智通财经APP讯,西点药业(301130.SZ)公告,公司截至2024年5月31日以集中竞价交易方式回购公司股份382.17万股,占公司目前总股本的4.7295%,成交总金额为8850.31万元(不含交易费用)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1130128.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","301130"],"gpt_icon":0},{"id":"2436014267","title":"西点药业:将参加吉林辖区上市公司网上集体业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2436014267","media":"中国财富通","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436014267?lang=zh_cn&edition=full","pubTime":"2024-05-20 13:53","pubTimestamp":1716184423,"startTime":"0","endTime":"0","summary":"中国财富通5月20日 - 西点药业(301130)公告称,为进一步加强与投资者的互动交流,公司将参加由吉林省证券业协会、全景网共同举办的“2024年吉林辖区上市公司网上集体业绩说明会”,时间为5月29日(星期三)15:00至16:30。届时公司董事长、总经理张俊,公司董事、副总经理石英秀,公司副总经理、董事会秘书张银姬,公司财务总监孟思,公司独立董事卢相君,海通证券股份有限公司保荐代表人赵琼琳将通过网络在线问答互动的形式,与投资者就2023年经营业绩等投资者关注的问题进行交流。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=C98aCODa3c4%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["301130","BK0239"],"gpt_icon":0},{"id":"2435134458","title":"西点药业:公司目前生产及在研产品中暂未使用生物合成相关技术","url":"https://stock-news.laohu8.com/highlight/detail?id=2435134458","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435134458?lang=zh_cn&edition=full","pubTime":"2024-05-13 17:08","pubTimestamp":1715591338,"startTime":"0","endTime":"0","summary":"证券之星消息,西点药业(301130)05月13日在投资者关系平台上答复投资者关心的问题。投资者:董秘你好,现在合成生物应用到很多领域,特别是医药这方面,请问公司有哪些产品用到了这方面西点药业董秘:尊敬的投资者,您好!公司目前生产及在研产品中暂未使用生物合成相关技术。公司会持续关注前沿科技在相关领域中的应用,谢谢!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051300017844.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301130","BK0239"],"gpt_icon":0},{"id":"2431321654","title":"4月30日西点药业发布公告,其股东减持83.22万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431321654","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431321654?lang=zh_cn&edition=full","pubTime":"2024-04-30 22:00","pubTimestamp":1714485655,"startTime":"0","endTime":"0","summary":"证券之星消息,4月30日西点药业发布公告《西点药业:关于持股5%以上股东及其一致行动人股份减持计划期限届满暨权益变动的提示性公告》,其股东国投高科技投资有限公司于2024年1月15日至2024年4月30日间合计减持83.22万股,占公司目前总股本的1.0299%,变动期间该股股价下跌6.83%,截止4月30日收盘报25.24元。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000053094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301130","BK0239"],"gpt_icon":0},{"id":"2431344911","title":"西点药业(301130.SZ)主要股东国投高科及其一致行动人完成减持1.03%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2431344911","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431344911?lang=zh_cn&edition=full","pubTime":"2024-04-30 20:35","pubTimestamp":1714480536,"startTime":"0","endTime":"0","summary":"智通财经APP讯,西点药业(301130.SZ)公告,公司持股5%以上股东国投高科技投资有限公司(简称“国投高科”)及其一致行动人杭州创合精选创业投资合伙企业(有限合伙)(简称“杭州创合”)通过集中竞价或大宗交易方式累计减持公司股份83.22万股,占公司总股本的1.03%。本次股份减持计划已实施完毕。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301130","BK0239"],"gpt_icon":0},{"id":"2429381704","title":"西点药业:公司发布的股东减持计划减持期间尚未到期,敬请关注公司后续发布的进展公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2429381704","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429381704?lang=zh_cn&edition=full","pubTime":"2024-04-24 18:04","pubTimestamp":1713953062,"startTime":"0","endTime":"0","summary":"证券之星消息,西点药业(301130)04月24日在投资者关系平台上答复投资者关心的问题。投资者:请问贵公司原始股东国投高科及一致行动人,减持股份完成了吗?减持价格是多少?西点药业董秘:尊敬的投资者,您好!公司发布的股东减持计划减持期间尚未到期,敬请关注公司后续发布的进展公告。谢谢!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400038078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301130"],"gpt_icon":0},{"id":"2429125062","title":"西点药业(301130)2024年一季报简析:营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2429125062","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429125062?lang=zh_cn&edition=full","pubTime":"2024-04-24 06:23","pubTimestamp":1713910993,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期西点药业发布2024年一季报。根据财报显示,本报告期中西点药业营收净利润同比双双增长。截至本报告期末,公司营业总收入6670.55万元,同比上升20.32%,归母净利润1404.28万元,同比上升46.66%。营收分析方面,公司最新一期年度报表的现金流为正,经营性现金流和利润相匹配。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400012292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301130"],"gpt_icon":0},{"id":"2429646972","title":"图解西点药业一季报:第一季度单季净利润同比增46.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429646972","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429646972?lang=zh_cn&edition=full","pubTime":"2024-04-23 01:49","pubTimestamp":1713808145,"startTime":"0","endTime":"0","summary":"证券之星消息,西点药业2024年一季报显示,公司主营收入6670.55万元,同比上升20.32%;归母净利润1404.28万元,同比上升46.66%;扣非净利润1206.11万元,同比上升90.22%;负债率6.72%,投资收益47.2万元,财务费用-199.73万元,毛利率78.05%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300002257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301130"],"gpt_icon":0},{"id":"2429971116","title":"图解西点药业年报:第四季度单季净利润同比增7.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429971116","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429971116?lang=zh_cn&edition=full","pubTime":"2024-04-23 00:42","pubTimestamp":1713804150,"startTime":"0","endTime":"0","summary":"证券之星消息,西点药业2023年年报显示,公司主营收入2.25亿元,同比下降11.73%;归母净利润5050.24万元,同比上升24.01%;扣非净利润2836.19万元,同比下降15.67%;其中2023年第四季度,公司单季度主营收入5499.53万元,同比下降22.82%;单季度归母净利润920.84万元,同比上升7.03%;单季度扣非净利润538.42万元,同比上升12.17%;负债率7.9%,投资收益777.32万元,财务费用-549.43万元,毛利率80.27%。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300000679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301130"],"gpt_icon":0},{"id":"2429225359","title":"西点药业最新公告:一季度净利润1404.28万元 同比增长46.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429225359","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429225359?lang=zh_cn&edition=full","pubTime":"2024-04-22 22:10","pubTimestamp":1713795016,"startTime":"0","endTime":"0","summary":"西点药业公布2024年一季度报告,报告期营业收入6670.55万元,同比增长20.32%;归属于上市公司股东的净利润1404.28万元,同比增长46.66%。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042200030255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301130"],"gpt_icon":0},{"id":"2429292719","title":"西点药业(301130.SZ)发一季度业绩,净利润1404.28万元,同比增长46.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429292719","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429292719?lang=zh_cn&edition=full","pubTime":"2024-04-22 21:32","pubTimestamp":1713792759,"startTime":"0","endTime":"0","summary":"智通财经APP讯,西点药业(301130.SZ)发布2024年第一季度报告,报告期内公司实现营业收入6670.55万元,同比增长20.32%;归属于上市公司股东的净利润1404.28万元,同比增长46.66%;归属于上市公司股东扣除非经常性损益净利润1206.11万元,同比增长90.22%;基本每股收益0.1738元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107058.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301130"],"gpt_icon":0},{"id":"2429181929","title":"西点药业(301130.SZ)发2023年度业绩,净利润5050.24万元,同比增长24.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429181929","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429181929?lang=zh_cn&edition=full","pubTime":"2024-04-22 21:30","pubTimestamp":1713792611,"startTime":"0","endTime":"0","summary":"智通财经APP讯,西点药业(301130.SZ)发布2023年年度报告,报告期内公司实现营业收入2.25亿元,同比减少11.73%;归属于上市公司股东的净利润5050.24万元,同比增长24.01%;归属于上市公司股东扣除非经常性损益净利润2836.19万元,同比减少15.67%;基本每股收益0.6250元/股。公司经本次董事会审议通过的利润分配预案为:以公司未来实施权益分派股权登记日的总股本扣除公司回购专用证券账户中股份数为基数,向全体股东每10股派发现金红利2.60元(含税),送红股0股(含税),以资本公积金向全体股东每10股转增0股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107050.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301130"],"gpt_icon":0},{"id":"2419929499","title":"西点药业(301130.SZ):盐酸艾司洛尔注射液获得注册申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2419929499","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2419929499?lang=zh_cn&edition=full","pubTime":"2024-03-15 11:54","pubTimestamp":1710474840,"startTime":"0","endTime":"0","summary":"西点药业(301130.SZ)发布公告,公司于近日收到国家药品监督管理局签发的盐酸艾司洛尔注射液境内生产药品补充申请《受理通知书》。根据国家相关法规规定,上述药品已获得注册申请受理,报送国家药监局药品审评中心进行审评审批。据悉,盐酸艾司洛尔注射液,用于治疗心房颤动、心房扑动时控制心室率,围手术期高血压,窦性心动过速。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-15/doc-inankpnu6865570.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-15/doc-inankpnu6865570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","301130"],"gpt_icon":0},{"id":"2419183698","title":"西点药业(301130.SZ)已累计回购2.1081%股份 耗资约3809.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2419183698","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2419183698?lang=zh_cn&edition=full","pubTime":"2024-03-14 07:48","pubTimestamp":1710373680,"startTime":"0","endTime":"0","summary":"西点药业(301130.SZ)发布公告,截至2024年3月13日,公司累计通过回购专用证券账户以集中竞价交易方式回购公司股份170.34万股,占公司目前总股本的2.1081%,最高成交价为23.50元/股,最低成交价为20.65元/股,成交总金额为3809.6万元。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-14/doc-inanftrx9928012.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-14/doc-inanftrx9928012.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301130","BK0239"],"gpt_icon":0},{"id":"2408926316","title":"西点药业(301130.SZ):枸橼酸钙境内生产药品注册上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2408926316","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2408926316?lang=zh_cn&edition=full","pubTime":"2024-02-02 07:55","pubTimestamp":1706831700,"startTime":"0","endTime":"0","summary":"西点药业发布公告,公司于近日收到国家药品监督管理局签发的枸橼酸钙境内生产药品注册上市许可申请《受理通知书》,国家药监局根据《中华人民共和国行政许可法》第三十二条的规定,经审查,决定予以受理。枸橼酸钙为钙剂,适用于预防和治疗多种钙缺乏症。本品参与骨骼的形成与骨折后骨组织的再建以及肌肉收缩,神经传递,凝血机制并降低毛细血管的渗透性,有助于补充机体钙质。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-02/doc-inafqyaf9789021.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-02/doc-inafqyaf9789021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301130","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-02-23","address":"吉林省吉林市磐石市磐石经济开发区西点大街777号","stockEarnings":[{"period":"1week","weight":-0.0162},{"period":"1month","weight":-0.0343},{"period":"3month","weight":-0.0096},{"period":"6month","weight":-0.0806},{"period":"1year","weight":-0.1695},{"period":"ytd","weight":-0.1623}],"companyName":"吉林省西点药业科技发展股份有限公司","boardCode":"AI0027","perCapita":"7080股","boardName":"医药制造业","registeredCapital":"8080万元","compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0186},{"period":"3month","weight":-0.031},{"period":"6month","weight":0.0459},{"period":"1year","weight":-0.0727},{"period":"ytd","weight":0.0005}],"survey":" 吉林省西点药业科技发展股份有限公司主营业务是化学药品原料药及制剂的研发、生产、销售。公司主要产品为复方硫酸亚铁叶酸片、利培酮口崩片、草酸艾司西酞普兰片、瑞香素胶囊、阿魏酸钠、阿魏酸钠、阿魏酸钠、阿魏酸钠。公司荣获“国家火炬计划重点高新技术企业”、等称号。","serverTime":1721219195067,"listedPrice":22.55,"stockholders":"8195人(较上一季度减少18.86%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.0","shortVersion":"4.25.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"西点药业(301130)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供西点药业(301130)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"西点药业,301130,西点药业股票,西点药业股票老虎,西点药业股票老虎国际,西点药业行情,西点药业股票行情,西点药业股价,西点药业股市,西点药业股票价格,西点药业股票交易,西点药业股票购买,西点药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"西点药业(301130)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供西点药业(301130)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}